Metastasis-directed radiotherapy for non-small cell lung cancer failured under TKI: A case report and literature review
We reported the case of a 38-year-old woman with metastatic ALKr-NSCLC who received whole-brain radiotherapy (RT) for multiple brain metastases (BMs), initially. After RT, alectinib was initiated and the patient had a good clinico-radiological response in both intracranial and extracranial regions. However, intracranial progression was developed and, stereotactic radiosurgery (SRS) was applied to the four progressed BMs. Two months after SRS, all BMs disappeared. While patient was using alectinib, a recurrent lung lesion, a hilar lymph node and bone metastasis were detected. Stereotactic body radiotherapy (SBRT) was applie...
Source: Cancer Radiotherapie - October 12, 2023 Category: Cancer & Oncology Authors: A Kahvecioglu S Kilickap P Hurmuz Source Type: research
Indication and perspectives of radiation therapy in the setting of de-novo metastatic prostate cancer
This article aims to define indications of radiotherapy and perspectives of this therapeutic option for de-novo metastatic prostate cancer.PMID:37827959 | DOI:10.1016/j.canrad.2023.05.004 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 12, 2023 Category: Cancer & Oncology Authors: I Latorzeff A Camps-Mal éa S Supiot R de Crevoisier M-P Farcy-Jacquet J-M Hannoun-L évi O Riou P Pommier X Artignan O Chapet G Cr éhange V Marchesi D Pasquier P Sargos Source Type: research
Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas
CONCLUSIONS: Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.PMID:37813717 | DOI:10.1016/j.canrad.2023.02.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 9, 2023 Category: Cancer & Oncology Authors: N Hanslik C Bourgier S Thezenas S Carr ère N Firmin O Riou D Azria C Llacer-Moscardo Source Type: research
Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas
CONCLUSIONS: Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.PMID:37813717 | DOI:10.1016/j.canrad.2023.02.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 9, 2023 Category: Cancer & Oncology Authors: N Hanslik C Bourgier S Thezenas S Carr ère N Firmin O Riou D Azria C Llacer-Moscardo Source Type: research
Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas
CONCLUSIONS: Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.PMID:37813717 | DOI:10.1016/j.canrad.2023.02.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 9, 2023 Category: Cancer & Oncology Authors: N Hanslik C Bourgier S Thezenas S Carr ère N Firmin O Riou D Azria C Llacer-Moscardo Source Type: research
Predictive factors assessment of pathological response to neoadjuvant radiotherapy of soft tissue sarcomas
CONCLUSIONS: Neoadjuvant radiotherapy is well-tolerated. No clinical, radiological or pathological predictive factors was identified for radiotherapy tumour response.PMID:37813717 | DOI:10.1016/j.canrad.2023.02.003 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 9, 2023 Category: Cancer & Oncology Authors: N Hanslik C Bourgier S Thezenas S Carr ère N Firmin O Riou D Azria C Llacer-Moscardo Source Type: research
Radiation therapy of the primary tumour and/or metastases of digestive metastatic cancers
Cancer Radiother. 2023 Oct 6:S1278-3218(23)00209-3. doi: 10.1016/j.canrad.2023.04.007. Online ahead of print.ABSTRACTMetastatic gastrointestinal cancer is not an uncommon situation, especially for pancreatic, gastric, and colorectal cancers. In this setting, few data are available on the impact of the treatment of the primary tumour. Oligometastatic disease is associated with longer survival in comparison with more advanced disease. Metastasis-directed therapy, such as stereotactic body radiotherapy, seems related to better outcomes, but the level of evidence is low. In most tumour locations, prospective data are very scar...
Source: Cancer Radiotherapie - October 8, 2023 Category: Cancer & Oncology Authors: F Huguet O Riou D Pasquier A Modesto L Qu éro M Michalet A Bordron B Schipman A Orthuon A Lisbona V Vendrely N Jaksic Source Type: research
Role of radiotherapy in the management of brain oligometastases
We present the recommendations of the French society of radiation oncology on the management of brain oligometastatic patients with radiotherapy.PMID:37802747 | DOI:10.1016/j.canrad.2023.03.005 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 6, 2023 Category: Cancer & Oncology Authors: D Antoni E Mesny O El Kabbaj S Josset G No ël J Biau L Feuvret I Latorzeff Source Type: research
Role of radiotherapy in the management of brain oligometastases
We present the recommendations of the French society of radiation oncology on the management of brain oligometastatic patients with radiotherapy.PMID:37802747 | DOI:10.1016/j.canrad.2023.03.005 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 6, 2023 Category: Cancer & Oncology Authors: D Antoni E Mesny O El Kabbaj S Josset G No ël J Biau L Feuvret I Latorzeff Source Type: research
Role of radiotherapy in the management of brain oligometastases
We present the recommendations of the French society of radiation oncology on the management of brain oligometastatic patients with radiotherapy.PMID:37802747 | DOI:10.1016/j.canrad.2023.03.005 (Source: Cancer Radiotherapie)
Source: Cancer Radiotherapie - October 6, 2023 Category: Cancer & Oncology Authors: D Antoni E Mesny O El Kabbaj S Josset G No ël J Biau L Feuvret I Latorzeff Source Type: research
Third whole-brain radiation therapy for multiple brain metastases. Should it be considered in selected patients?
Cancer Radiother. 2023 Sep 28:S1278-3218(23)00205-6. doi: 10.1016/j.canrad.2023.05.003. Online ahead of print.ABSTRACTWhole brain reirradiation for the treatment of multiple brain metastases has shown promising results. However, concerns remain over the possible neurotoxic effects of the cumulative dose as well as the questionable radiosensitivity of recurrent metastases. A second reirradiation of the whole brain is ordinarily performed in our department for palliative purposes in patients presenting with multiple metastatic brain progression. For this study, an investigational third whole brain reirradiation has been admi...
Source: Cancer Radiotherapie - September 30, 2023 Category: Cancer & Oncology Authors: L Lapadula M Piombino A Bianculli R Caivano A Capobianco A Cacciatore M Cozzolino C Oliviero B D'andrea A Mileo A Leone F Carbone N P Fochi M Landriscina A Colamaria G Giordano Source Type: research
Third whole-brain radiation therapy for multiple brain metastases. Should it be considered in selected patients?
Cancer Radiother. 2023 Sep 28:S1278-3218(23)00205-6. doi: 10.1016/j.canrad.2023.05.003. Online ahead of print.ABSTRACTWhole brain reirradiation for the treatment of multiple brain metastases has shown promising results. However, concerns remain over the possible neurotoxic effects of the cumulative dose as well as the questionable radiosensitivity of recurrent metastases. A second reirradiation of the whole brain is ordinarily performed in our department for palliative purposes in patients presenting with multiple metastatic brain progression. For this study, an investigational third whole brain reirradiation has been admi...
Source: Cancer Radiotherapie - September 30, 2023 Category: Cancer & Oncology Authors: L Lapadula M Piombino A Bianculli R Caivano A Capobianco A Cacciatore M Cozzolino C Oliviero B D'andrea A Mileo A Leone F Carbone N P Fochi M Landriscina A Colamaria G Giordano Source Type: research
Third whole-brain radiation therapy for multiple brain metastases. Should it be considered in selected patients?
Cancer Radiother. 2023 Sep 28:S1278-3218(23)00205-6. doi: 10.1016/j.canrad.2023.05.003. Online ahead of print.ABSTRACTWhole brain reirradiation for the treatment of multiple brain metastases has shown promising results. However, concerns remain over the possible neurotoxic effects of the cumulative dose as well as the questionable radiosensitivity of recurrent metastases. A second reirradiation of the whole brain is ordinarily performed in our department for palliative purposes in patients presenting with multiple metastatic brain progression. For this study, an investigational third whole brain reirradiation has been admi...
Source: Cancer Radiotherapie - September 30, 2023 Category: Cancer & Oncology Authors: L Lapadula M Piombino A Bianculli R Caivano A Capobianco A Cacciatore M Cozzolino C Oliviero B D'andrea A Mileo A Leone F Carbone N P Fochi M Landriscina A Colamaria G Giordano Source Type: research
Third whole-brain radiation therapy for multiple brain metastases. Should it be considered in selected patients?
Cancer Radiother. 2023 Sep 28:S1278-3218(23)00205-6. doi: 10.1016/j.canrad.2023.05.003. Online ahead of print.ABSTRACTWhole brain reirradiation for the treatment of multiple brain metastases has shown promising results. However, concerns remain over the possible neurotoxic effects of the cumulative dose as well as the questionable radiosensitivity of recurrent metastases. A second reirradiation of the whole brain is ordinarily performed in our department for palliative purposes in patients presenting with multiple metastatic brain progression. For this study, an investigational third whole brain reirradiation has been admi...
Source: Cancer Radiotherapie - September 30, 2023 Category: Cancer & Oncology Authors: L Lapadula M Piombino A Bianculli R Caivano A Capobianco A Cacciatore M Cozzolino C Oliviero B D'andrea A Mileo A Leone F Carbone N P Fochi M Landriscina A Colamaria G Giordano Source Type: research
Third whole-brain radiation therapy for multiple brain metastases. Should it be considered in selected patients?
Cancer Radiother. 2023 Sep 28:S1278-3218(23)00205-6. doi: 10.1016/j.canrad.2023.05.003. Online ahead of print.ABSTRACTWhole brain reirradiation for the treatment of multiple brain metastases has shown promising results. However, concerns remain over the possible neurotoxic effects of the cumulative dose as well as the questionable radiosensitivity of recurrent metastases. A second reirradiation of the whole brain is ordinarily performed in our department for palliative purposes in patients presenting with multiple metastatic brain progression. For this study, an investigational third whole brain reirradiation has been admi...
Source: Cancer Radiotherapie - September 30, 2023 Category: Cancer & Oncology Authors: L Lapadula M Piombino A Bianculli R Caivano A Capobianco A Cacciatore M Cozzolino C Oliviero B D'andrea A Mileo A Leone F Carbone N P Fochi M Landriscina A Colamaria G Giordano Source Type: research
